Lisata Therapeutics closes Marea Therapeutics merger and $225M private placement, with pro forma financials
Lisata Therapeutics completed its acquisition of Marea Therapeutics on September 17, 2026, issuing common stock and Series C Non-Voting Convertible Preferred Stock to Marea holders. A concurrent private placement of Series C preferred to institutional investors closed September 18 for about $225.0 million gross. Following stockholder approval and conversion, former Marea holders are expected to own about 59.5% of the combined company, PIPE investors about 38.1% and legacy Lisata holders about 2.4%; the filing presents unaudited pro forma combined financials.
Company's press release (SEC filing): Lisata Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants
Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
